**Machine learning identifies unique taxa differentiating proximal and distal human colonic microbiota**

Running title: Specific taxa differentiate proximal and distal human colon microbiota

Kaitlin J. Flynn1, Charles C. Koumpouras1, Mack T. Ruffin IV2, Danielle Kimberly Turgeon3, and Patrick D. Schloss1

Corresponding author: [pschloss@umich.edu](mailto:pschloss@umich.edu)

1. Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109

2. Pennslyvania State University, Hershey, Pennslyvania ??

3. Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michigan

### Abstract

Colorectal cancer (CRC) remains a leading cause of death worldwide. Tumors of the proximal (right) and distal (left) colon are morphologically and genetically distinct. Previous work from our group found that microbial dysbiosis is associated with the development of CRC tumors in studies of both mice and humans. Analysis of the fecal microbiota from healthy and CRC patients further revealed different microbial signatures associated with disease. In this study, we extended our observations of the fecal microbiome to analysis of the proximal and distal human colon. We used a two-colonoscope approach on subjects that had not undergone standard bowel preparation procedure. This technique allowed us to characterize the native proximal and distal luminal and mucosal microbiome without prior chemical disruption. 16S rRNA gene sequencing was performed on proximal and distal mucosal and luminal biopsies and exit stool for 20 healthy individuals. Diversity analysis revealed that each site contained a diverse community, and that a patient’s samples were more similar to each other than to that of other individuals. Since we could not differentiate sites along the colon based on community structure or community membership alone, we employed the machine-learning algorithm Random Forest to identify key species that distinguish biogeographical sites. Random Forest classification models were built using taxa abundance and sample location and revealed distinct populations that were found in each location. *Peptoniphilus, Anaerococcus, Enterobacteraceae, Pseudomonas* and *Actinomyces* were most likely to be found in mucosal samples versus luminal samples (AUC = 0.925). The classification model performed well (AUC = 0.912) when classifying mucosal samples into proximal or distal sides, but separating luminal samples from each side proved more challenging (AUC = 0.755). The left mucosa was found to have high populations of *Finegoldia, Murdochiella* and *Porphyromonas*. Proximal and distal luminal samples were comprised of many of the same taxa, likely reflecting the fact that stool moves along the colon from the proximal to distal end. Finally, comparison of all samples to fecal samples taken at exit uncovered that the feces were most similar to samples taken from the left lumen, again reflecting the anatomical structure of the colon. Taken together, our results have identified distinct bacterial populations of the proximal and distal colon. Further investigation of these bacteria may elucidate if and how these groups contribute to differential oncogenesis processes on the respective sides of the colon.

### Introduction

Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths in the United States. CRC tumors vary in structure, size, morbidity and symptomology depending upon their geographical location in the colon. CRC has recently been described to fall into four molecular subtypes ((1)). Of these subtypes, tumors that arise on the left side of the colon are infiltrating lesions that present with painful symptoms. In contrast, right-sided colon tumors are bulky and project into the lumen, often causing no symptoms until they have developed into carcinomas ((2)). Because of the absence of symptoms, right-sided tumors, which comprise up to 47% of CRCs, have a significantly higher mortality rate ((2)). The left and right sides of the colon differ in the amount of inflammation present and the genomic instability of precancerous cells, respectively, as well as oxygen, pH and the presence of antimicrobial peptides ((3), (4), (5)). Microenvironments differ not only longitutinally along the colon, but latitudinally from the epithelium to mucosa to intestinal lumen, offering several sites for different microbial communities to flourish. Given this varied physiology of the proximal-distal axis of the colon, symbiotic microbes and their metabolites likely vary between sites.

Several recent findings have shown that development and progression of CRC can be attributed to specific molecular events as a result of interactions between the gut microbiota and human host ((3)). Our group and others have found that the stool microbiome of patients with CRC is distinct from that of healthy people ((6)). Further studies manipulating the gut microbiome using antibiotics or other chemoagents in mice has shown that dysbiosis preceded and accelerated the development of CRC tumors ((7)). Comparison of the specific bacteria present on CRC tumors with those found on nearby healthy tissue has also identified specific bacterial species that are tumor-associated based on FISH staining and 16S rRNA sequencing ((8)). These species include the oral pathogens *Fusobacterium nucleatum* and *Porphyromonas asacharolytica*. Interestingly, the periodontal pathogens are also highly predictive of if a patient has CRC tumors or not in our classification studies ((9)). However, these studies have been performed comparing shed stool or in mice, which does not allow for analysis of paried samples from the proximal and distal sides of the colon. Similarly, comparisons of on- or off-tumor bacteria rarely have matched tissue from the other side of the colon from the same patient, limiting what conclusions can be drawn about the colonic microbiome overall, let alone at that specific site. Disruption of the healthy community could promote the initiation or proliferation of the distinct left and right CRC tumors. However, the contribution of the gut microbiota to these subtypes is largely undefined.

Furthermore, profiles of the microbial biogeography of the gut have been limited by sample collection methods. The majority of human gut microbiome studies have been performed on whole shed stool or on samples collected during colonoscopy procedures. While the latter method allows investigators to acquire samples from inside the human colon, typically this procedure is preceded by the use of bowel preparation methods such as the consumption of laxatives to cleanse the bowel. Bowel preparation is essential for detecting cancerous or precancerous lesions in the colon, but complicates microbiome profiling as the chemicals strip the bowel of contents and disrupt the mucosal layer ((10), (11)). As such, what little information we do have about the biogeographical distribution of the microbes in the proximal and distal colon is confounded by the bowel preparation procedure.

In this study we sought to combine these approaches to characterize the microbiome in the lumen and mucosa of the proximal and distal healthy human colon. Our design uses unprepared colonoscopy techniques to sample each location of the gut without prior disruption of the native flora in 20 healthy volunteers. To get around the noise created by a diverse set of human microbiomes, we used a machine-learning classification algorithm trained on curated 16S rRNA sequencing reads to identify microbes specific to each location. We found that our classification models were able to separate mucosal and lumenal samples as well as differentiate between sides of the colon based on populations of specific microbes. By identifying the specific microbes we are poised to ask if and how the presence or disruption of the microbes at each site contribute to the development of the specific tumor subtypes of CRC in the proximal and distal human colon.

### Results

#### Microbial membership and diversity of the proximal and distal colon

Proximal and distal lumenal and mucosal samples were collected from 20 healthy humans that had not undergone bowel preparation(Figure 1). Participants also collected stool at home one week prior to the procedure. To characterize the bacterial communities present at these sites, 16S rRNA gene sequencing was performed on extracted DNA from each sample. The relative abundance of each phyla for each site is shown in Figure 2A. This data combines the samples from all participants in the study. Each site is primarily dominated by *Firmicutes* and *Bacteriodetes*, consistent with known variability in human microbiome research. Likewise, samples had varying levels of diversity at each site, irrespective of the individual (Figure 2B). That is, while some individuals had a more diverse right mucosa, some had a more diverse left mucosa, and so on. Therefore we could not identify a clear pattern of changes in microbial diversity along the gut axis.

To compare similarity between sides (left or right) or sites (lumen or mucosa), we calculated theta YC distances from OTU abundances and compared distances for all individuals. Again, across all patient samples we saw a range of theta YC distances when comparing sample locations (Figure 3A) and again those ranges did not follow a clear pattern on an individual basis. However, when comparing median distances between the right lumen and mucosa, the left versus right lumen, the left versus right mucosa and the left lumen and mucosa, we found that the right lumen and mucosa were most similar to each other than the other samples (P < 0.005, Wilcoxon, BH adjustment). Next, we calculated thetaYC distances to examine how each sample compared to the home-collected exit stool. Amidst variability between patients, we did identify significantly smaller thetaYc distance between the left lumenal sample and the exit stool (Figure 3B, P < 0.05, Wilcoxon, BH adjustment). Further, there was an even larger difference in the comparisons of the left mucosa to the exit stool, indicating that the mucosa is quite different from the stool as compared to lumen (P < 0.0005, Wilcoxon, BH adjustment). To determine what factors may be driving the differences seen among the samples, we compared thetaYC distances between samples from all subjects (interpersonal) versus samples from within one subject (intrapersonal). We found that samples from one individual were overall much more similar to each other than to other study subjects (Figure 3C), consistent with previous human microbiome studies that have sampled multiple sites of the human colon (**???**). Thus interpersonal variation between subjects drives the differences between samples more than sample site or location. Overall, the results of the similarity analysis suggest that the contents of the left lumen are most representative of stool at exit, and the microbes remaining on the mucosa are much different.

#### Random Forest classification models identify important OTUs on each side

To identify OTUs that were distinct at each biogeographical site, we constructed several Random Forest machine-learning models built on OTU abundances. The first model we built to classify the lumen versus mucosal samples for the right and left sides, independently (Figure 4A). The constructed model used ((Xopt)) features for the right and ((Xopt)) for the left. The models performed well when classifying these samples (AUC = 0.797 and AUC = 0.980, respectively). The OTUs that were most predictive of each site are identified by their greatest mean decrease in accuracy when removed from the model. For distinguishing the right lumen and mucosa, OTUs from the *Bacteriodes*, *Actinomyces*, *Psuedomonas* and two OTUs from the *Enterobacteraceae* genera were differentially abundant (Figure 4B). The model classifying the left lumen and mucosa identified OTUs from *Turicibacter*, *Finegoldia*, *Peptoniphilus* and two OTUs from the *Anaerococcus* genera that could distinguish lumen from mucosal samples (Figure 4C). These results indicate that there are fine differences between the different sites of the colon, and that these can be traced down to specific OTUs on each side.

Next, we built a model to differentiate the left and right microbiome. The model performed best when distinguishing the right versus left mucosa (Figure 5A, AUC = 0.912) compared to the right versus left lumen (AUC = 0.755). The model was able to explain ((X%)) of the variance. OTUs that were differentially abundant between the left and right mucosa included members of the *Porphyromonas*, *Murdochiella*, *Finegoldia*, *Anaerococcus* and *Peptoniphilus* genera (Figure 5B). The model was less-effective at classifying the right and left lumen (AUC = 0.755). However it did identify differentially abundant OTUs such as three members of the *Bacteroides* genus, a *Clostridium IV* OTU and an *Oscillibacter* OTU (Figure 5C). This analysis found that some of the same OTUs that are distinct between the mucosa and lumen also drive sidedness- such as *Anaerococcus* and *Finegoldia*.

#### Bacterial OTUs associated with cancer are found in healthy individuals

Given that specific bacterial species have been associated with colorectal cancer we probed our sample set for these OTUs. Among our 100 samples, the most frequent sequence associated wtih the *Fusobacterium* genus was OTU179, which BLASTs to *Fusobacterium nucleatum subsp animalis*. It was the only sequence to align with a *F. nucleatum* strain- the only species of *Fusobacterium* known to have oncogenic properties and be found on the surfaces of colorectal cancer tumors. ((12)). The *Fusobacterium* positive samples were located on the right and left mucosa and ranged up to 1% of the sample (Figure 6A). OTU00152 is *Porphyromonas* and the most frequent sequence in that OTU aligns to *Porphyromonas asacharolytica*, another bacterium commonly detected and isolated from colorectal tumors. OTU152 was only detected on the left mucosa, and in fact was one of the OTUs the classification model identified as separating left and right sides (Figure 6B). Samples that were positive for *P. asacharolytica* ranged in abundances from 0.01% - 16%. Thus, cancer-associated OTUs could be found in our sample set of 20 healthy individuals.

### Discussion

Here we identified bacterial taxa that are specific to the lumen and mucosa of the right and left human colon from samples collected during unprepared colonoscopy. We found that all locations contained a range of phyla and a range of diversity, but that there was a wide variability between subjects. Pairwise comparisons of each of the sites revealed that the right mucosa and lumen were most similar to each other. Further, comparison of colonoscopy-collected samples with samples collected from stool at home showed that the left lumen is most similar to stool at exit. Random Forest algorithms built on OTU abundances from each sample identified microbes that are particular to each location of the colon. Finally, we were able to detect some bacterial OTUs associated with colorectal cancer in our healthy patient cohort. Using unprepped colonoscopy and machine learning, we have identified bacterial phyla specific to the healthy proximal and distal human colon.

When examining the relative abundance of the different phyla at each site, there is a wide amount of variation for each phyla with communities primarily dominated by the Bacteriodes and Firmicutes. This likely reflects not only the variability between human subjects, casued by differences in age, gender, diet, but also reports of microbial "patchiness" in the gut microbiome. Several previous studies have noted that the bacteria recoverable from the same mucosal sample location can be vastly different when the samples are taken just 1 cm away from each other ((13)). Similar patchiness is also observed in lumenal contents and fecal samples themselves; there is observed separation of different interacting microbes along the length of a stool sample, for instance ((14)). That said, across our samples the mucosal samples harbor more Proteobacteria, consistent with previous studies comparing mucosal swabs to lumenal content in humans ((4)). Hence, the conclusions we can draw from phyla analysis are likely confounded by differences in sampling and patchiness between subjects.

We identified a range of Simpson diversity values between patients and between each anatomical site. As this measurement takes both number of species and abundance of species into account, it seems that there is a varied level of each component along the human colon. There was no clear pattern of diversity when comparing patients- some patients had a higher level of diversity in the proximal than the distal colon, some patients had the opposite. An early study of microbial diversity and membership of three human subjects found a varied level of diversity in each subject, but that subjects were overall more similar to themselves than to each other (**???**). We used the thetaYC dissimilarity metric to compare the communities present at each anatomical location to each other. We found that while there was a wide range of similarity of each site within a person, the study participants were ultimately more similar to themselves than all of the other participants. This finding is consistent with numerous studies examining the biogeography of the colon in healthy humans (**???**, (15), (16)).

To get around the noisiness created by a diverse set of samples, we built a Random Forest model to identify microbes specific to each side. For each comparison we identified top X OTUs that were strongly predictive of one site or another. Generally, OTUs identified in each location were consistent with known physiological gradients along the gut axis ((5)). For instance, the right mucosa harbored mucosa-associated facultative anaerobes such as *Actinomyces* and *Enterobacteraceae* and the aerobic *Psuedomonas* consistent with the highest oxygen regions of the colon. The left mucosa was far more likely to host strictly anaerobic species such as *Porphyromonas*, *Anaerococcus*, *Finegoldia* and *Peptoniphilus*. The model was less effective at classifying the right and left lumenal contents, probably because the samples are arguably composed of the same material.

We detected *F. nucleatum* and *P. asacharolytica* in 7 and 5 of our subjects, respectively. These bacteria have been shown to be predictive of colorectal cancer in humans ((9)) and have oncogenic properties in cell culture and in mice ((17)). Interestingly, while *F. nucleatum* was found on both sides of the colon, *P. asacharolytica* was only detected in the left mucosa. Not much is known about the distribution of *P. asacharolytica* but given its documented anaerobic characteristics and asacharolytic metabolism, it might not be surprising that it resides in the less-oygen-rich and proteinaceous left mucosa ((4)). In studies examining bacteria on colorectal cancer tumors, *F. nucleatum* is more commonly detected on right-sided tumors, and distribution of *F. nucleatum* decreases along the colon to rectum ((18)). Of the (8) (40%) individuals positive for *F. nucleatum* in this study, the bacteria was spread across the right mucosa, left lumen and left mucosa. That said, in a previous study of 1,102 colorectal cancer cases, only 138 (11%) of them contained detectable *F. nucleatum* at all ((18)). In a separate study of patients with inflammatory bowel disease (IBD), 50% of 22 IBD patients and 17.6% of 34 people without disease contained *F. nucleatum* in mucosal biopsies ((19)). These studies have the added caveat of being sampled from prepared or cleaned colons. Thus, the presence of *F. nucleatum* in a healthy individual is not necessarily linked to the development of future colorectal cancers. Because of the spatial distribution of the *F. nucleatum* in our sample set, we cannot develop a model for the role of *F. nucleatum* in the healthy colon. Indeed, rather than the *F. nucleatum* initiating tumorigenesis, these bacteria may instead arrive "late" to the tumor microenvironment and feed on tumors that have alread begun to develop ((20)). Data examining bacterial biofilms on CRC tumors suggests that *Fusobacteria* species are more commonly found both on proximal tumors and in biofilms, indicating that it is not only the presence of the bacteria but the organization of the tumor community that contributes to *Fusobacterium's* role in tumorigenesis. Finally, *Fusobacteria* and *Porphyromonas* species have been known to not only co-occur on CRC tumors but also to synergistically promote tumorigenesis in an oral cancer model ((21), (20)). Thus, further analysis of the distribution and role of these pathogens may elucidate a mechanism for development of CRC tumors in the proximal or distal colon.

Specific comparisons of our findings to previously published gut biogeography studies are additionally confounded by the use of bowel preparation methods in most other studies. A rare report of a matched-colonoscopy study that sampled 18 patient's colonic mucosa and lumenal contents prior to and after bowel cleansing ((22)). This group found that mucosa and lumenal samples were distinguishable prior to bowel cleansing, but that bowel preparation resulted in an increase in shared OTUs between each site ((22)). Bowel cleansing not only made the samples harder to distinguish, it resulted in decreases in diversity across sites. Further, the differences were not great enough to overcome interpersonal differences between subjects. So, bowel preparation clearly induces bias into the microbes recovered from sampling the lumen or mucosa of a prepared bowel. Thus our findings of specific bacteria at each site of the colon are strengthened by the lack of bowel preparation.

Microbiome-based diagnostics are increasingly being explored as non-invasive tools to survey for the development of colon cancer. Random Forest models have been used by our group and others to increase the detection sensitivity of CRC tumors. Indeed, our group found that a classification model that used microbiome data in combination with Fecal Immunohistochemical Test (FIT) results could correctly identify both carcinoma and adenoma lesions from communities of stool at exit and it performed much better than FIT alone. Further work from our lab has shown that microbiome profiling of the FIT cartridge contents sufficiently represented the stool community ((9)). One caveat of the FIT study was that there was not sufficient information to test if a classification model could differentiate between proximal and distal CRC tumors based on exit stool sample alone, but we would hypothesize that would not be effective. Given that our results showed that the stool most accurately reflects the community of the left lumen, we likely cannot use Random Forest of stool samples to diagnose any changes in the proximal or mucosal communities.

By revealing specific differences in microbial populations at each location in the gut via sampling an unprepared bowel, we can begin to form hypothesies about how specific host-microbe interactions can affect oncogenesis of proximal and distal CRC tumors. To this point, 16S community profiling studies do not provide enough information to probe these questions. Our sample set of matched proximal, distal, lumenal and mucosal samples from colons that have not undergone bowel preparation presents a unique opportunity to explore further questions about the microbiome along the gut axis. Specifically, examining metagenomic, metabolomic and host interactions at each site will be useful in further characterizing the host-microbe interactions in the development of proximal and distal colorectal cancer.

### Acknowledgments

We thank all the individuals who volunteered for the study. This work was supported by the Rose and Lawrence C. Page Foundation (DKT). We would also like to thank Brian Kleiner, Chelsea Crofoot, and Kirk Herman for their roles in study coordination, subject recruitment, sample collection and sample processing.

### Methods

#### Human subjects

The procedures in this study and consent were approved by the Institutional Review Board at the University of Michigan Health System with protocol number XXXX. Subjects were recruited using the online recruitment platform and were pre-screened prior to enrollment in the study. Exclusion criteria included: use of asprin or NSAIDs within 7 days, use of antibiotics within 3 months, current use of anticoagulants, known allergies to Fentanyl or Benadryl, prior history of colon disease, diabetes, abdominal surgery, respiratory, liver, kidney or brain impairments, undergoing current chemotherapy or radiation treatment and subjects that were pregnant or trying to conceive. 20 subjects that met the criteria were selected and provided signed informed consent prior to the procedure. There were 13 female and 7 male subjects ranging in age from 25 to 64.

#### Sample collection

At a baseline visit, subjects were consented and given a home collection stool kit (Source of kit supplies). At least one week prior to the scheduled colonoscopy, subjects were to collect whole stool at home and two swabs of a Fecal Immunohistochemical Test cartridge (Polymedco Inc.) and ship the samples to the University. Notably, subjects did not undergo any bowel preparation method prior to sampling. On procedure day, subjects reported to the Michigan Clinical Research Unit at the University of Michigan Health System. Patients were consciously sedated using Fentanyl, Versed and/or Benadryl as appropriate. A flexible sigmoidoscope was first inserted about 25cm into the colon and endoscopy brush used to collect lumenal/stool contents. Two lumenal samples were collected and the contents immediately deposited into RNAlater (source) and flash-frozen in liquid nitrogen. The brushes were withdrawn and biopsy forceps were used to collect mucosal biopsies on sections of the colon that were pink and free of stool matter. Three mucosal biopsies were collected and flash-frozen in RNAlater. These samples comprised the distal or left colon samples. The sigmoidoscope was then withdrawn and a pediatric colonoscope was inserted to reach the ascending colon. Samples were then collected as in the distal colon and the colonoscope withdrawn. All samples were stored at -80 C until study completion.

#### Sample processing, sequencing and analysis

DNA extraction was performed using the PowerMicrobiome DNA/RNA Isolation Kit (MO BIO Laboratories). For tissue biopsies, Bond-Breaker TCEP solution (Fisher) and 2.8mm ceramic beads (MO BIO Laboratories) were added to the bead beating step to enhance DNA recovery from mucosal samples. The resulting DNA was used as template for amplification of the V4 region of the 16S rRNA gene and fragments were sequenced on an Illumina MiSeq as previously described ((23)). Sequences were curated using the mothur software as described previously ((24)). The sequences were assigned taxonomic classification using a naive Bayesian classifier trained using a 16S rRNA gene training set from the Ribosomal Database Project (RDP) ((25)) and clustered into operational taxonomic units (OTUs) based on a 97% similarity cutoff. Sequencing and analysis of a mock community revealed the error rate to be X%. Samples were rarefied to 4231 sequences per sample in order to reduce sampling bias.

Diversity analysis was performed using the Simpson diversity calculator and theta YC calculator metrics in mothur ((24)). ThetaYC distances were calculated to determine the dissimilarity between two samples. Random Forest classification models were built using the randomForest R package and resultant models were used to identify the OTUs that were most important for classifying each location ((26)). To get species-level information about sequences of interest, sequences were aligned using blastn and the species name was only used if the identity score was >= 99%.

#### Statistical analysis

Differences in community membership at the phyla level were tested using the analysis of molecular variance (AMOVA) metric in mothur. Differences in thetaYC distances by location were tested using the Wilcoxon rank-sum test adjusted for multiple comparisons using the Benjamini-Hochberg procedure.

### Figure legends

#### Figure 1

Sampling strategy. A flexible sigmoidoscope was used to sample the distal colonic luminal contents and mucosa. The scope was inserted ~ 25cm into the subject and endoscopy brushes were used to sample the luminal contents (green star). A separate set of biopsy forceps was used to sample the distal mucosa (blue star). The sigmoidoscope was removed. A pediatric colonoscope was inserted and used to access the proximal colon. Biopsies were taken of the proximal luminal contents and mucosa as described. One week prior to the procedure stool was collected at home and sent into the laboratory. Representative images from one individual are shown.

#### Figure 2

Microbial membership and diversity of the proximal and distal human colon. A) Relative abundance of the top five bacterial phyla in each sampling site. Each box represents the median and confidence intervals. B) Simpson diversity of the microbial communities at each location. The lines represent the median values.

#### Figure 3

Similarity of microbial community structure between sites of the gut. ThetaYC distances are shown for interpersonal similarities between two sites – each point represents one individual. In (A), comparisons of the right and left mucosal and lumen are shown. In (B), comparisons of each site to the exit stool are shown.

#### Figure 4

Random Forest classifies the mucosa and lumen of each side of the colon. A) Receiver Operator Characteristic curves are shown for the 10-fold cross validation of the Random Forest model classifying lumen and mucosal samples for the left and right sides of the colon. (B) Top five OTUs that are most important for the classification model for the left mucosa and lumen (B) and the right mucosa and lumen (C).

#### Figure 5

Random Forest classifies the left and right sides of the colon. A) Receiver Operator Characteristic curves are shown for the 10-fold cross validation of the Random Forest model classifying left lumen versus right lumen (orange) and left mucosa vs right mucosa (green). (B) Top five OTUs that are most important for the classification model for the left and right mucosa (B) and the left and right lumen (C).

#### Figure 6

Location and abundance of cancer-associated OTUs. Relative abundance was calculated and plotted by sample site for each OTU of interest: (A) *Fusobacterium nucleatum* and (B) *Porphyromonas asacharolytica*

### References

1. **Guinney J**, **Dienstmann R**, **Wang X**, **Reyniès A de**, **Schlicker A**, **Soneson C**, **Marisa L**, **Roepman P**, **Nyamundanda G**, **Angelino P**, **Bot BM**, **Morris JS**, **Simon IM**, **Gerster S**, **Fessler E**, **Melo FDSE**, **Missiaglia E**, **Ramay H**, **Barras D**, **Homicsko K**, **Maru D**, **Manyam GC**, **Broom B**, **Boige V**, **Perez-Villamil B**, **Laderas T**, **Salazar R**, **Gray JW**, **Hanahan D**, **Tabernero J**, **Bernards R**, **Friend SH**, **Laurent-Puig P**, **Medema JP**, **Sadanandam A**, **Wessels L**, **Delorenzi M**, **Kopetz S**, **Vermeulen L**, **Tejpar S**. 2015. The consensus molecular subtypes of colorectal cancer. Nature Medicine **21**:1350–1356. doi:[10.1038/nm.3967](https://doi.org/10.1038/nm.3967).

2. **Benedix F**, **Kube R**, **Meyer F**, **Schmidt U**, **Gastinger I**, **Lippert H**. 2010. Comparison of 17, 641 patients with right- and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Diseases of the Colon & Rectum **53**:57–64. doi:[10.1007/dcr.0b013e3181c703a4](https://doi.org/10.1007/dcr.0b013e3181c703a4).

3. **Yamauchi M**, **Lochhead P**, **Morikawa T**, **Huttenhower C**, **Chan AT**, **Giovannucci E**, **Fuchs C**, **Ogino S**. 2012. Colorectal cancer: A tale of two sides or a continuum?: Figure 1. Gut **61**:794–797. doi:[10.1136/gutjnl-2012-302014](https://doi.org/10.1136/gutjnl-2012-302014).

4. **Albenberg L**, **Esipova TV**, **Judge CP**, **Bittinger K**, **Chen J**, **Laughlin A**, **Grunberg S**, **Baldassano RN**, **Lewis JD**, **Li H**, **Thom SR**, **Bushman FD**, **Vinogradov SA**, **Wu GD**. 2014. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology **147**:1055–1063.e8. doi:[10.1053/j.gastro.2014.07.020](https://doi.org/10.1053/j.gastro.2014.07.020).

5. **Donaldson GP**, **Lee SM**, **Mazmanian SK**. 2015. Gut biogeography of the bacterial microbiota. Nature Reviews Microbiology **14**:20–32. doi:[10.1038/nrmicro3552](https://doi.org/10.1038/nrmicro3552).

6. **Zackular JP**, **Rogers MAM**, **Ruffin MT**, **Schloss PD**. 2014. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prevention Research **7**:1112–1121. doi:[10.1158/1940-6207.capr-14-0129](https://doi.org/10.1158/1940-6207.capr-14-0129).

7. **Zackular JP**, **Baxter NT**, **Iverson KD**, **Sadler WD**, **Petrosino JF**, **Chen GY**, **Schloss PD**. 2013. The gut microbiome modulates colon tumorigenesis. mBio **4**:e00692–13–e00692–13. doi:[10.1128/mbio.00692-13](https://doi.org/10.1128/mbio.00692-13).

8. **Dejea CM**, **Wick EC**, **Hechenbleikner EM**, **White JR**, **Welch JLM**, **Rossetti BJ**, **Peterson SN**, **Snesrud EC**, **Borisy GG**, **Lazarev M**, **Stein E**, **Vadivelu J**, **Roslani AC**, **Malik AA**, **Wanyiri JW**, **Goh KL**, **Thevambiga I**, **Fu K**, **Wan F**, **Llosa N**, **Housseau F**, **Romans K**, **Wu X**, **McAllister FM**, **Wu S**, **Vogelstein B**, **Kinzler KW**, **Pardoll DM**, **Sears CL**. 2014. Microbiota organization is a distinct feature of proximal colorectal cancers. Proceedings of the National Academy of Sciences **111**:18321–18326. doi:[10.1073/pnas.1406199111](https://doi.org/10.1073/pnas.1406199111).

9. **Baxter NT**, **Ruffin MT**, **Rogers MAM**, **Schloss PD**. 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Medicine **8**. doi:[10.1186/s13073-016-0290-3](https://doi.org/10.1186/s13073-016-0290-3).

10. **Jalanka J**, **Salonen A**, **Salojärvi J**, **Ritari J**, **Immonen O**, **Marciani L**, **Gowland P**, **Hoad C**, **Garsed K**, **Lam C**, **Palva A**, **Spiller RC**, **Vos WM de**. 2014. Effects of bowel cleansing on the intestinal microbiota. Gut **64**:1562–1568. doi:[10.1136/gutjnl-2014-307240](https://doi.org/10.1136/gutjnl-2014-307240).

11. **Harrell L**, **Wang Y**, **Antonopoulos D**, **Young V**, **Lichtenstein L**, **Huang Y**, **Hanauer S**, **Chang E**. 2012. Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colon. PLoS ONE **7**:e32545. doi:[10.1371/journal.pone.0032545](https://doi.org/10.1371/journal.pone.0032545).

12. **Castellarin M**, **Warren RL**, **Freeman JD**, **Dreolini L**, **Krzywinski M**, **Strauss J**, **Barnes R**, **Watson P**, **Allen-Vercoe E**, **Moore RA**, **Holt RA**. 2011. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Research **22**:299–306. doi:[10.1101/gr.126516.111](https://doi.org/10.1101/gr.126516.111).

13. **Hong P-Y**, **Croix JA**, **Greenberg E**, **Gaskins HR**, **Mackie RI**. 2011. Pyrosequencing-based analysis of the mucosal microbiota in healthy individuals reveals ubiquitous bacterial groups and micro-heterogeneity. PLoS ONE **6**:e25042. doi:[10.1371/journal.pone.0025042](https://doi.org/10.1371/journal.pone.0025042).

14. **Stearns JC**, **Lynch MDJ**, **Senadheera DB**, **Tenenbaum HC**, **Goldberg MB**, **Cvitkovitch DG**, **Croitoru K**, **Moreno-Hagelsieb G**, **Neufeld JD**. 2011. Bacterial biogeography of the human digestive tract. Scientific Reports **1**. doi:[10.1038/srep00170](https://doi.org/10.1038/srep00170).

15. **Cárcer DA de**, **Cuív PÓ**, **Wang T**, **Kang S**, **Worthley D**, **Whitehall V**, **Gordon I**, **McSweeney C**, **Leggett B**, **Morrison M**. 2010. Numerical ecology validates a biogeographical distribution and gender-based effect on mucosa-associated bacteria along the human colon. The ISME Journal **5**:801–809. doi:[10.1038/ismej.2010.177](https://doi.org/10.1038/ismej.2010.177).

16. **Zhang Z**, **Geng J**, **Tang X**, **Fan H**, **Xu J**, **Wen X**, **Ma Z (Sam)**, **Shi P**. 2013. Spatial heterogeneity and co-occurrence patterns of human mucosal-associated intestinal microbiota. The ISME Journal **8**:881–893. doi:[10.1038/ismej.2013.185](https://doi.org/10.1038/ismej.2013.185).

17. **Sears CL**, **Garrett WS**. 2014. Microbes, microbiota, and colon cancer. Cell Host & Microbe **15**:317–328. doi:[10.1016/j.chom.2014.02.007](https://doi.org/10.1016/j.chom.2014.02.007).

18. **Mima K**, **Cao Y**, **Chan AT**, **Qian ZR**, **Nowak JA**, **Masugi Y**, **Shi Y**, **Song M**, **Silva A da**, **Gu M**, **Li W**, **Hamada T**, **Kosumi K**, **Hanyuda A**, **Liu L**, **Kostic AD**, **Giannakis M**, **Bullman S**, **Brennan CA**, **Milner DA**, **Baba H**, **Garraway LA**, **Meyerhardt JA**, **Garrett WS**, **Huttenhower C**, **Meyerson M**, **Giovannucci EL**, **Fuchs CS**, **Nishihara R**, **Ogino S**. 2016. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clinical and Translational Gastroenterology **7**:e200. doi:[10.1038/ctg.2016.53](https://doi.org/10.1038/ctg.2016.53).

19. **Strauss J**, **Kaplan GG**, **Beck PL**, **Rioux K**, **Panaccione R**, **DeVinney R**, **Lynch T**, **Allen-Vercoe E**. 2011. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflammatory Bowel Diseases **17**:1971–1978. doi:[10.1002/ibd.21606](https://doi.org/10.1002/ibd.21606).

20. **Flynn KJ**, **Baxter NT**, **Schloss PD**. 2016. Metabolic and community synergy of oral bacteria in colorectal cancer. mSphere **1**:e00102–16. doi:[10.1128/msphere.00102-16](https://doi.org/10.1128/msphere.00102-16).

21. **Whitmore SE**, **Lamont RJ**. 2014. Oral bacteria and cancer. PLoS Pathogens **10**:e1003933. doi:[10.1371/journal.ppat.1003933](https://doi.org/10.1371/journal.ppat.1003933).

22. **Shobar RM**, **Velineni S**, **Keshavarzian A**, **Swanson G**, **DeMeo MT**, **Melson JE**, **Losurdo J**, **Engen PA**, **Sun Y**, **Koenig L**, **Mutlu EA**. 2016. The effects of bowel preparation on microbiota-related metrics differ in health and in inflammatory bowel disease and for the mucosal and luminal microbiota compartments. Clinical and Translational Gastroenterology **7**:e143. doi:[10.1038/ctg.2015.54](https://doi.org/10.1038/ctg.2015.54).

23. **Kozich JJ**, **Westcott SL**, **Baxter NT**, **Highlander SK**, **Schloss PD**. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq illumina sequencing platform. Applied and Environmental Microbiology **79**:5112–5120. doi:[10.1128/aem.01043-13](https://doi.org/10.1128/aem.01043-13).

24. **Schloss PD**, **Westcott SL**, **Ryabin T**, **Hall JR**, **Hartmann M**, **Hollister EB**, **Lesniewski RA**, **Oakley BB**, **Parks DH**, **Robinson CJ**, **Sahl JW**, **Stres B**, **Thallinger GG**, **Horn DJV**, **Weber CF**. 2009. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Applied and Environmental Microbiology **75**:7537–7541. doi:[10.1128/aem.01541-09](https://doi.org/10.1128/aem.01541-09).

25. **Wang Q**, **Garrity GM**, **Tiedje JM**, **Cole JR**. 2007. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Applied and Environmental Microbiology **73**:5261–5267. doi:[10.1128/aem.00062-07](https://doi.org/10.1128/aem.00062-07).

26. **Liaw A**, **Wiener M**. 2002. Classification and regression by randomForest. R News: The Newsletter of the R Project **2**:18–22.